Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Allakos	Blueprint Medicines	Ionis Pharmaceuticals	Galapagos	TG Therapeutics
Symbol	NASDAQ:ALLK	NASDAQ:BPMC	NASDAQ:IONS	NASDAQ:GLPG	NASDAQ:TGTX
Price Information
Current Price	$91.24	$83.69	$37.78	$69.22	$37.91
52 Week Range	Buy	Buy	Hold	Hold	Buy
MarketRank™
Overall Score	1.5	2.2	1.6	1.5	1.8
Analysis Score	3.5	4.3	3.2	4.1	3.4
Community Score	2.3	2.9	2.3	2.6	3.3
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	0.0	1.7
Earnings & Valuation Score	0.0	1.9	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Hold	Buy
Consensus Price Target	$197.67	$114.93	$58.05	$129.20	$64.00
% Upside from Price Target	116.64% upside	37.33% upside	53.64% upside	86.65% upside	68.82% upside
Trade Information
Market Cap	$4.89 billion	$4.88 billion	$5.33 billion	$4.54 billion	$5.36 billion
Beta	0.92	0.69	1.09	0.57	2.16
Average Volume	249,390	468,402	1,469,681	285,436	1,445,985
Sales & Book Value
Annual Revenue	N/A	$793.73 million	$729 million	$605.66 million	$150,000.00
Price / Sales	N/A	6.15	7.31	7.49	35,753.68
Cashflow	N/A	$5.55 per share	N/A	N/A	N/A
Price / Cash	N/A	15.09	N/A	N/A	N/A
Book Value	$12.46 per share	$26.38 per share	$6.03 per share	$46.63 per share	$3.95 per share
Price / Book	N/A	3.17	6.27	1.48	9.60
Profitability
Net Income	$-153,480,000.00	$313.88 million	$-451,290,000.00	$-348,900,000.00	$-279,380,000.00
EPS	($3.10)	$5.59	($3.23)	($5.36)	($2.42)
Trailing P/E Ratio	N/A	14.87	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	40.18%	-69.63%	-45.08%	-35,158.99%
Return on Equity (ROE)	-34.01%	27.25%	-41.74%	-10.05%	-95.94%
Return on Assets (ROA)	-31.27%	22.74%	-18.24%	-4.76%	-73.19%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	1.28%	N/A	N/A
Current Ratio	27.48%	8.34%	6.74%	8.77%	5.78%
Quick Ratio	27.48%	8.20%	6.67%	8.77%	5.78%
Ownership Information
Institutional Ownership Percentage	72.92%	99.11%	86.17%	10.05%	69.11%
Insider Ownership Percentage	34.45%	3.34%	2.96%	2.91%	10.20%
Miscellaneous
Employees	141	451	757	1,304	301
Shares Outstanding	53.57 million	58.34 million	140.96 million	65.52 million	141.47 million
Next Earnings Date	8/9/2021 (Estimated)	7/29/2021 (Estimated)	8/4/2021 (Estimated)	8/5/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Not Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	Looking Into TG Therapeutics's Return On Capital Employed benzinga.com - June 23 at 11:30 AM
	Interesting TGTX Put And Call Options For February 2022 nasdaq.com - June 21 at 2:58 PM
	TG Therapeutics, Inc. (NASDAQ:TGTX) Expected to Announce Earnings of -$0.48 Per Share americanbankingnews.com - June 20 at 9:10 PM
	With 52.96% Distance From Low, Is TG Therapeutics Inc. (NASDAQ:TGTX) Poised For More Gains? marketingsentinel.com - June 19 at 11:38 AM
	TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology finance.yahoo.com - June 18 at 5:38 PM
	TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma finance.yahoo.com - June 18 at 12:38 PM
	TG Therapeutics Inc. (NASDAQ: TGTX) Inclined 3.96% Over The Last Month – Are There Ways To Succeed From This Incline? marketingsentinel.com - June 12 at 5:05 PM
	TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress finance.yahoo.com - June 11 at 7:44 AM
	TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma finance.yahoo.com - June 9 at 7:24 AM
	Return On Capital Employed Overview: TG Therapeutics benzinga.com - June 7 at 12:36 PM
	TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting finance.yahoo.com - June 4 at 10:06 AM
	TG Therapeutics Inc. (NASDAQ: TGTX) Continues To Decline stocksregister.com - June 2 at 2:48 PM
	TG Therapeutics, Inc. (NASDAQ:TGTX)’s Share Price Fell Recently, Although No Trouble Is On The Horizon stocksregister.com - May 25 at 11:30 PM
	H.C. Wainwright Stick to Their Buy Rating for TG Therapeutics investing.com - May 25 at 6:29 PM
	TG Therapeutics, Inc. (TGTX) has great growth outlook for 2021 marketingsentinel.com - May 25 at 1:29 PM
	TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma finance.yahoo.com - May 25 at 8:29 AM
	First Week of July 16th Options Trading For TG Therapeutics (TGTX) nasdaq.com - May 23 at 11:52 AM
	Is TG Therapeutics, Inc. (NASDAQ:TGTX) a Good Pick for New Investors Now? stocksregister.com - May 21 at 5:12 PM
	Boom Or Bust: Where Does TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Go From Here? marketingsentinel.com - May 21 at 5:12 PM
	TG Therapeutics, Inc. (NASDAQ:TGTX) Surprises Bears With Its Outlook marketingsentinel.com - May 18 at 3:00 PM
	TG Therapeutics Inc (TGTX) Q1 2021 Earnings Call Transcript finance.yahoo.com - May 10 at 9:30 PM
	TG Therapeutics (TGTX) Reports Q1 Loss, Lags Revenue Estimates finance.yahoo.com - May 10 at 4:30 PM
	TG Therapeutics: Q1 Earnings Snapshot mysanantonio.com - May 10 at 7:48 AM
	TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results finance.yahoo.com - May 10 at 7:48 AM
	TG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business Update finance.yahoo.com - May 6 at 11:57 AM

Date	Company	Brokerage	Action
5/18/2021	Allakos	HC Wainwright	Initiated Coverage
2/24/2021	Allakos	Cantor Fitzgerald	Initiated Coverage
1/15/2021	Allakos	Bank of America	Initiated Coverage
12/21/2020	Allakos	SVB Leerink	Initiated Coverage
10/22/2020	Allakos	Lifesci Capital	Reiterated Rating
3/26/2020	Allakos	William Blair	Reiterated Rating
2/27/2020	Allakos	Barclays	Initiated Coverage
2/4/2020	Allakos	The Goldman Sachs Group	Reiterated Rating
8/13/2018	Allakos	Jefferies Financial Group	Initiated Coverage
6/17/2021	Blueprint Medicines	Wedbush	Lower Price Target
6/17/2021	Blueprint Medicines	Robert W. Baird	Boost Price Target
4/30/2021	Blueprint Medicines	Morgan Stanley	Lower Price Target
3/30/2021	Blueprint Medicines	Credit Suisse Group	Initiated Coverage
12/18/2020	Blueprint Medicines	JMP Securities	Boost Price Target
12/14/2020	Blueprint Medicines	BMO Capital Markets	Boost Price Target
12/2/2020	Blueprint Medicines	Stifel Nicolaus	Initiated Coverage
10/29/2020	Blueprint Medicines	Piper Sandler	Boost Price Target
10/16/2020	Blueprint Medicines	Raymond James	Boost Price Target
5/7/2021	Ionis Pharmaceuticals	UBS Group	Upgrade
3/23/2021	Ionis Pharmaceuticals	Needham & Company LLC	Lower Price Target
3/23/2021	Ionis Pharmaceuticals	Royal Bank of Canada	Lower Price Target
12/15/2020	Ionis Pharmaceuticals	Cowen	Upgrade
10/7/2020	Ionis Pharmaceuticals	Oppenheimer	Reiterated Rating
9/14/2020	Ionis Pharmaceuticals	JPMorgan Chase & Co.	Initiated Coverage
4/20/2021	Galapagos	Deutsche Bank Aktiengesellschaft	Initiated Coverage
2/11/2021	Galapagos	Citigroup	Downgrade
2/10/2021	Galapagos	Maxim Group	Downgrade
12/17/2020	Galapagos	Smith Barney Citigroup	Reiterated Rating
12/17/2020	Galapagos	Bryan, Garnier & Co	Downgrade
2/5/2021	TG Therapeutics	B. Riley	Boost Price Target
6/5/2020	TG Therapeutics	Evercore ISI	Initiated Coverage

(Data available from 6/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources